UK small-cap RNS · 27 Jul 2026
Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.
Sort: Newest · Largest companies
-
07:00
H1 2026 Trading Update Trading updateThe Board only 'remains confident in meeting' unchanged FY2026 expectations (US$14.0m revenue, US$4.0m adjusted EBITDA). Guidance is confirmed, not raised, but H1 cash, EBITDA and repeat business support the H2-weighted plan.ahead of expectationsoutlook positive +3.6% on the dayMoved: Post-IPO growth investment: IPO funds deployed; CTO hired, dev team built → Investments made; sign-ups up, payback expected H2 · new: Largest contract delivery – Delivery ongoing, progressing as planned
-
07:00
-
07:00
-
07:00
Big Technologies BIG £268mTrading Update and Notice of Results("Big Technologies" or "the Company" and, together with its subsidiaries, the "Group")+0.6% on the day
-
07:00
-
07:00
Science Group SAG £229mHalf-year Results ResultsH1 adjusted operating profit edged up to £11.5m on a margin of 24.3%, but core revenue fell to £46.4m and cash fell year on year as defence delays and geopolitics weighed.Moved: Share buyback programme: Ongoing; 8.8% bought back in past year → 2.4m shares bought in H1 for £13.5m · UK Defence contracting delays: Defence Investment Plan deferred; CMS2 contracts progressing → DIP released July 2026; improvement seen · new: Freehold property options review – Advisers appointed, evaluating options
-
07:00
-
07:00
-
07:00
-
07:00
Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trialInside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients.in linefirst in 9 months +2.5% on the day
-
07:00